⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Official Title: A Phase I/II Assessment of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 (BMS-986016) and Anti-TIGIT (BMS-986207)

Study ID: NCT04150965

Study Description

Brief Summary: This a Phase I/II randomized trial for patients with relapsed refractory Multiple Myeloma who have relapsed after treatment with prior therapies. The protocol is designed to evaluate two agents, Anti-LAG-3 and Anti-TIGIT, in order to understand their immunologic effects and safety both as single agents and in combination with pomalidomide and dexamethasone. In these arms, patients will be treated with either Anti-LAG-3 or Anti-TIGIT respectively for one cycle as single agent followed by the addition of pomalidomide and dexamethasone in combination for subsequent cycles. A third arm allows patients to be treated with the FDA approved combination of elotuzumab plus pomalidomide and dexamethsone as a control. This arm will thus allow a concurrent standard of care comparator for the experimental arms.

Detailed Description: This study will enroll 104 patients to one of three treatment arms. The study is open to patients relapsing with refractory Multiple Myeloma who have: * received 3 prior lines of therapy * exposed to each of these 3 drug classes: * IMiD * proteasome inhibitors, and * anti-CD38 monoclonal antibody * relapsed and refractory are defined using the IMWG criteria: * disease that is non-responsive while on salvage therapy or progresses within 60 days of last therapy in patients who have achieved minimal response or better at some point previously to then progressing in their disease course.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Emory University, Atlanta, Georgia, United States

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Dana Farber Cancer Institute, Boston, Massachusetts, United States

University of Michigan, Ann Arbor, Michigan, United States

Washington University School of Medicine Division of Medical Oncology, Saint Louis, Missouri, United States

Hackensack Meridian Medical Center, Hackensack, New Jersey, United States

Mount Sinai School of Medicine, New York, New York, United States

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Levine Cancer Institute, Charlotte, North Carolina, United States

UT Southwestern Medical Center, Dallas, Texas, United States

Contact Details

Name: Madhav V. Dhodapkar, M.D.

Affiliation: Medical Monitor

Role: PRINCIPAL_INVESTIGATOR

Name: Hearn J. Cho, M.D., Ph.D.

Affiliation: Chief Medical Officer

Role: PRINCIPAL_INVESTIGATOR

Name: Daniel Auclair, Ph.D.

Affiliation: Chief Scientific Officer

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: